Shareholder Rights Advocates at Levi & Korsinsky Investigate Iovance Biotherapeutics, Inc. (IOVA) Regarding Possible Securities

  • NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Iovance Biotherapeutics, Inc. ("Iovance Biotherapeutics, Inc.") (NASDAQ:IOVA) concerning possible violations of federal securities laws. On May 8, 2025, after the market closed, Iovance issued their first quarter fiscal 2025 results well below expectations, announcing a loss of 36 cents per share on revenue of $49 million.